INSP Stock Forecast & Price Target

Inspire Medical Systems is expected to continue its positive performance, driven by the launch of the new Inspire V device, improved inventory dynamics and patient warehousing, and a decrease in long-term GLP-1 concerns. Despite potential challenges in the reimbursement landscape, the company has maintained strong revenue growth and profits, with a projected 6% increase in sales for 2027. Additionally, the company has seen success in penetrating more accounts and benefiting from a mix shift and lower operating expenses, leading to a significant beat in first quarter revenue and adjusted earnings per share.

Inspire Medical Systems is facing significant challenges in the short term as their 2026 guidance was weaker than expected, with a decline in revenue and earnings. This is due to reimbursement issues and competition in the market, which are expected to persist through 2026 and potentially into 2027. While Inspire's technology and market position are still attractive in the long term, the uncertainty and disruptions caused by reimbursement issues make it difficult to maintain a confident outlook for the stock. The decrease in the company's revenue and earnings outlook, as well as the potential for further declines in the stock's valuation, led to a downgrade to a Neutral rating and a lower price target of $55 from $85.